Canaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $142 from $130 and keeps a Buy rating on the shares. The firm’s target changed following an update to its model as a result of the positive Phase III ROSELLA outcome. They continue to be bullish on the shares given the strength of uptake in Korlym over the past two years. They believe the market potential for Korlym is quite significant and that their model projections are conservative.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Buy Recommendation for Corcept Therapeutics Driven by Promising Phase 3 ROSELLA Study Results and Market Expansion Potential
- Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz
- Corcept Therapeutics price target raised to $128 from $78 at Piper Sandler
- Corcept Therapeutics price target raised to $150 from $76 at Truist
- Corcept Therapeutics: Promising Future with Positive Trial Results and Strong Market Position